Drug intelligence / Profile preview

BSI-500

Development stage: Preclinical
Lead developer: Biosion
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BSI-500 is a first-in-class bispecific antibody currently in development by Biosion for the treatment of solid tumors. As a bispecific molecule, it is designed to simultaneously engage two different targets or epitopes, which may provide synergistic therapeutic effects or overcome resistance mechanisms associated with traditional monoclonal antibodies. While the specific molecular targets of BSI-500 have not been publicly disclosed in the company's pipeline, it is positioned as an innovative oncology asset within their biologics portfolio aimed at addressing unmet needs in solid cancer therapy.

Beyond the preview

Go deeper on BSI-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSI-500.

Explore the full profile